SCHEMBL1960579

SCHEMBL1960579

COc1ccc2ccn3c(=O)cc(-c4ccncc4)nc3c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 6/20 0.40
CYP2D6 P10635 4/20 0.40
PDE5A O76074 1/20 0.40
CDC7 O00311 2/20 0.40
ROCK2 O75116 2/20 0.40
PIM1 P11309 2/20 0.40
HIPK2 Q9H2X6 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
MAP4K4 O95819 1/20 0.40
PRKACA P17612 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
KMT2A Q03164 2/20 0.39
TP53 P04637 2/20 0.39
NPC1 O15118 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Maleic Acid SCHEMBL1960105 0.92 CYP3A4 (0.39) GSK3BCYP2D6PDE5ACDC7ROCK2
Fumaric Acid SCHEMBL1960107 0.92 CYP3A4 (0.39) GSK3BCYP2D6PDE5ACDC7ROCK2
SCHEMBL1837492 0.87 PSD (0.39) GSK3BCYP2D6ROCK2KMT2ATP53
SCHEMBL1835187 0.85 GSK3B (0.43) GSK3BCYP2D6MAPT
SCHEMBL1840178 0.81 GSK3B (0.39) GSK3BCDC7ROCK2PIM1HIPK2
SCHEMBL1835853 0.81 GSK3B (0.39) GSK3BCDC7ROCK2PIM1HIPK2
SCHEMBL1839402 0.80 PRKDC (0.54) GSK3BCDC7ROCK2PIM1HIPK2
Oxalic Acid SCHEMBL1835999 0.77 CYP2C9 (0.41) GSK3BCDC7ROCK2PIM1HIPK2
SCHEMBL1839427 0.73 GSK3B (0.45) GSK3BCDC7ROCK2PIM1HIPK2
SCHEMBL1838129 0.71 GSK3B (0.41) GSK3BCDC7ROCK2PIM1HIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321313-B1 SUBSTITUTED PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE DERIVATIVES AS GSK3 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-09-02 EP claimed
US-8211903-B2 Substituted pyrimido isoquinoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-07-03 US claimed
US-20110144138-A1 SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES SANOFI-AVENTIS (FR) 2011-06-16 US claimed
EP-2138495-A1 Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives sanofi-aventis (FR) 2009-12-30 EP claimed
EP-2321313-B1 SUBSTITUTED PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE DERIVATIVES AS GSK3 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-09-02 EP disclosed
US-8211903-B2 Substituted pyrimido isoquinoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-07-03 US disclosed
US-20110144138-A1 SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES SANOFI-AVENTIS (FR) 2011-06-16 US disclosed
EP-2138495-A1 Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives sanofi-aventis (FR) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144138-A1 SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES RECQL, QDPR, IFNAR1 GSK3B 4110/4885CYP2D6 374/4885PDE5A 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.